ChemPlusChem
October 1, 2020
Claudius Lenz, Alexander M. Sherwood, Robert B. Kargbo et al.
40 citations
Abstract Psychotropic fungi of the genus Psilocybe , colloquially referred to as „magic mushrooms”, are best known for their l ‐tryptophan‐derived major natural product, psilocybin. Yet, recent research has revealed a more diverse secondary metabolism that originates from this amino acid. In this minireview, the focus is laid on l ‐tryptophan and the various Psilocybe natural products and their...
International Journal of Molecular Sciences
September 7, 2020
Matas Vitkauskas, Ajay S. Mathuru
4 citations
Depression impacts the lives and daily activities of millions globally. Research into the neurobiology of lateral habenula circuitry and the use of psychedelics for treating depressive states has emerged in the last decade as new directions to devise interventional strategies and therapies. Several clinical trials using deep brain stimulation of the habenula, or using ketamine, and psychedelics...
Frontiers in Synaptic Neuroscience
August 21, 2020
Simon Vann Jones, Allison O’kelly
60 citations
Currently, there are no disease-modifying treatments for Alzheimer's disease (AD) or any other dementia subtype. The renaissance in psychedelic research in recent years, in particular studies involving psilocybin and lysergic acid diethylamide (LSD), coupled with anecdotal reports of cognitive benefits from micro-dosing, suggests that they may have a therapeutic role in a range of psychiatric...
Irish Journal of Psychological Medicine
August 19, 2020
John R. Kelly, Matthew Crockett, Laith Alexander et al.
16 citations
The medium- to long-term consequences of COVID-19 are not yet known, though an increase in mental health problems are predicted. Multidisciplinary strategies across socio-economic and psychological levels may be needed to mitigate the mental health burden of COVID-19. Preliminary evidence from the rapidly progressing field of psychedelic science shows that psilocybin therapy offers a promising...
Schizophrenia Bulletin
August 5, 2020
Pantelis Leptourgos, Martin Fortier-Davy, Robin Carhart-Harris et al.
88 citations
Abstract The recent renaissance of psychedelic science has reignited interest in the similarity of drug-induced experiences to those more commonly observed in psychiatric contexts such as the schizophrenia-spectrum. This report from a multidisciplinary working group of the International Consortium on Hallucinations Research (ICHR) addresses this issue, putting special emphasis on hallucinatory...
Psychopharmacology
July 23, 2020
Nige Netzband, Simon Ruffell, Sabriya Linton et al.
56 citations
Abstract Abstract Ayahuasca is a psychoactive plant brew containing dimethyltryptamine (DMT) and monoamine oxidase inhibitors (MAOIs). It originates from the Amazon basin, where it is used primarily for ceremonial purposes. Ayahuasca tourists are now entering certain communities seeking alternative physical or psychological healing, as well as spiritual growth. Rationale Recent evidence has...
Journal of Neurology, Neurosurgery, and Psychiatry
July 20, 2020
Matthew Butler, Mathieu Seynaeve, Timothy R. Nicholson et al.
Aims Functional neurological disorder (FND), formerly known as conversion disorder, causes a high burden of disability and distress, and is amongst the most commonly encountered conditions in neurology clinics and neuropsychiatry services, yet the therapeutic evidence base is limited. Research into psychedelics such as psilocybin and lysergic acid diethylamide (LSD) is currently being...
Journal of Neurology, Neurosurgery, and Psychiatry
July 20, 2020
Robin Carhart-Harris
Robin Carhart-Harris moved to Imperial College London in 2008 after obtaining a PhD in Psychopharmacology from the University of Bristol and an MA in Psychoanalysis from Brunel University. At Imperial, he has designed and/or carried out brain imaging studies involving LSD, psilocybin, MDMA and DMT, plus a clinical trial of psilocybin for treatment-resistant depression, and an ongoing study...
Journal of Psychopharmacology
July 17, 2020
Carl A Roberts, Isaac Osborne-Miller, Jon C. Cole et al.
33 citations
Background: Data on actual harm of magic mushrooms suggest that toxicity and abuse potential is low, however, their legal status suggests otherwise. We aimed to gauge perception of harm of magic mushrooms in both users and mushroom-naïve participants. We also aimed to observe differences in expectations of effects between users and mushroom-naïve participants, and whether motivations for use...
The MIT Press eBooks
July 14, 2020
Ido Hartogsohn
34 citations
How historical, social, and cultural forces shaped the psychedelic experience in midcentury America, from CIA LSD experiments the Harvard Psilocybin Project. Are psychedelics invaluable therapeutic medicines, or dangerously unpredictable drugs that precipitate psychosis? Tools for spiritual communion or cognitive enhancers that spark innovation? Activators for one's private muse or part of a...